Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11657045 | 0.85 | HPGD (0.43) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL11656947 | 0.84 | HPGD (0.41) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL29523202 | 0.81 | EHMT2 (0.55) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL9888690 | 0.79 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL30495965 | 0.79 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL11216281 | 0.79 | EHMT2 (0.42) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| Bicarbonate SCHEMBL5534135 | 0.76 | EHMT2 (0.48) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL7818128 | 0.76 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL9967715 | 0.76 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL5061383 | 0.76 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111559976-B | Synthetic method of heteroaryl thioether | 扬州大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-111559976-A | Synthetic method of heteroaryl thioether | 扬州大学 | 2020-08-21 | — | — | CN | disclosed |
| CN-110300578-A | For treating the compound of ox or porcine respiratory disease | 英特维特国际股份有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-9416080-B2 | Catalytic C—H bond activation | GEORGETOWN UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416080-B2 | Catalytic C—H bond activation | GEORGETOWN UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2999484-A1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | Shire Human Genetic Therapies, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150321982-A1 | Catalytic C-H Bond Activation | NATIONAL SCIENCE FOUNDATION | 2015-11-12 | — | — | US | disclosed |
| US-20150321982-A1 | Catalytic C-H Bond Activation | NATIONAL SCIENCE FOUNDATION | 2015-11-12 | — | — | US | disclosed |
| WO-2014190316-A1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| JP-2000351767-A | PRODUCTION OF THIOETHER AND THIOL | SANKYO CO LTD | 2000-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150321982-A1 | Catalytic C-H Bond Activation | CBR3, CBR1, SOD3 | HPGD 2541/4885SMN1; SMN2 4125/4885HSD17B10 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.